IQVIA Holdings Inc. (IQV) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-17

How it makes money

IQVIA earns revenue by providing clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare industries.

IQVIA generates revenue primarily by delivering outsourced clinical research, technology solutions, analytics, and commercial services to biopharmaceutical, medical device, and healthcare clients. The company operates through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Profitability is driven by the volume of outsourced clinical trials, the expansion of proprietary healthcare data assets, and the successful execution of technology and analytics contracts across global markets.

What protects it: the moat

Proprietary healthcare data collections, advanced privacy-enhancing technologies, and extensive global IT infrastructure protect IQVIA from competitors.

Management states that the company maintains one of the largest and most comprehensive collections of healthcare information globally, encompassing billions of longitudinal patient records and petabytes of proprietary data sourced from hundreds of thousands of suppliers.

Additionally, the company relies on sophisticated tokenization engines, privacy-enhancing technologies, and domain expertise to standardize and integrate complex datasets that would be difficult for competitors to replicate.

What growth costs

IQVIA reinvests capital through strategic business combinations, technology development, and operational expansion across its segments.

The company invests capital to acquire businesses that strengthen and expand its offerings across its reportable segments. During the year, the company invested $1,714 million, net of cash, to acquire businesses and maintained ongoing cash flows from operating activities of $2,654 million.

The filing does not provide a separate numerical breakdown for ongoing maintenance capital expenditures versus growth capital expenditures.

What could damage it

The loss of data supplier relationships could restrict access to vital information, impair analytics offerings, and materially harm operating results.

IQVIA depends on approximately 150,000 data suppliers to provide the feeds necessary for its healthcare intelligence platform. If these suppliers restrict the use of or refuse to license data, IQVIA would be unable to access certain data or provide certain services, directly undermining its proprietary information assets and damaging financial performance.

About IQVIA Holdings Inc.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

More on IQV

Other companies in Diagnostics & Research